Department of Otorhinolaryngology, The University-Town Hospital of Chongqing Medical University, Chongqing, China.
Department of Otorhinolaryngology, Huangshi Central Hospital, Affiliated Hospital of Hubei Polytechnic University, Edong Healthcare Group, Huangshi, China;
Allergol Immunopathol (Madr). 2022 May 1;50(3):15-23. doi: 10.15586/aei.v50i3.528. eCollection 2022.
Tumor necrosis factor and HNRNPL-related immunoregulatory long noncoding RNA (lnc-THRIL) and its target microRNA (miR)-125b are reported to regulate immune response through several means by participating in allergic rhinitis (AR) pathology. This study aimed to investigate the role of lnc-THRIL and miR-125b in detecting AR risk, and to further explore their correlation with disease severity and cytokines released from T helper type (Th) 1 and Th2 in AR patients.
A total of 160 AR patients and 80 subjects with severe snoring symptoms (as controls) were recruited. Nasal mucosa samples were collected to measure the expressions of lnc-THRIL, miR-125b, and Th1 and Th2 cytokines by reverse transcription quantitative polymerase chain reaction.
The expression of lnc-THRIL decreased while that of miR-125b increased in AR patients when compared with that of controls, and further receiver operating characteristic curve showed that both could well distinguish AR patients from controls. Furthermore, lnc-THRIL negatively correlated with miR-125b in AR patients. lnc-THRIL was negatively correlated with Individual Nasal Symptom Score (INSS) (including nasal rhinorrhea score, sneezing score, and congestion score) and Total Nasal Symptom Score (TNSS), and miR-125b was positively associated with INSS (including itching score, sneezing score, and congestion score) and TNSS. Moreover, lnc-THRIL was correlated with increased Th1 cytokines (interferon-gamma (IFN-γ) and interleukin (IL)-2) but with decreased Th2 cytokines (IL-4 and IL-10), while miR-125b exhibited opposite trends in AR patients.
lnc-THRIL and its target (miR-125b) relate to disease risk, symptom severity, and Th1/Th2 imbalance of AR, suggesting their potential as biomarkers for AR management.
肿瘤坏死因子和 HNRNPL 相关免疫调节长链非编码 RNA（lnc-THRIL）及其靶 microRNA（miR-125b）被报道通过参与变应性鼻炎（AR）病理学，通过多种方式调节免疫反应。本研究旨在探讨 lnc-THRIL 和 miR-125b 在检测 AR 风险中的作用，并进一步探讨它们与 AR 患者 T 辅助型（Th）1 和 Th2 释放的细胞因子之间的相关性。
共招募 160 例 AR 患者和 80 例严重打鼾症状患者（作为对照组）。采集鼻黏膜样本，通过逆转录定量聚合酶链反应测量 lnc-THRIL、miR-125b 和 Th1 和 Th2 细胞因子的表达。
与对照组相比，AR 患者的 lnc-THRIL 表达降低，miR-125b 表达升高，进一步的受试者工作特征曲线表明，两者均能很好地区分 AR 患者和对照组。此外，AR 患者的 lnc-THRIL 与 miR-125b 呈负相关。lnc-THRIL 与个体鼻部症状评分（INSS）（包括鼻分泌物评分、打喷嚏评分和鼻塞评分）和总鼻部症状评分（TNSS）呈负相关，而 miR-125b 与 INSS（包括瘙痒评分、打喷嚏评分和鼻塞评分）和 TNSS 呈正相关。此外，lnc-THRIL 与 Th1 细胞因子（干扰素-γ（IFN-γ）和白细胞介素（IL）-2）的增加相关，而与 Th2 细胞因子（IL-4 和 IL-10）的减少相关，而 AR 患者的 miR-125b 则呈现相反的趋势。
lnc-THRIL 及其靶标（miR-125b）与 AR 的疾病风险、症状严重程度和 Th1/Th2 失衡有关，提示它们作为 AR 管理的生物标志物的潜力。
